Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pneumococcal Pneumonia vaccine Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pneumonia Vaccine in Aging HIV Positive Individuals

NCT02558751
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
23-valent pneumococcal polysaccharide vaccine, 13-valent pneumococcal conjugate vaccine
Biological
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
50 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional

Pneumonia Vaccine Education Intervention Study

NCT06136832
View directory record Official record
Conditions
Pneumonia, Pneumococcal, Vaccine
Interventions
Pneumococcal Vaccine Education
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years to 64 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting Phase 2 Interventional

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

NCT05183854
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal Polyvalent Vaccine
Biological
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Recombinant Attenuated Salmonella Typhi Vaccine Vectors Producing Streptococcus Pneumoniae PspA

NCT01033409
View directory record Official record
Conditions
Pneumonia
Interventions
Salmonella Typhi-vectored pneumonia vaccine
Biological
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 1, 2011 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effectiveness of the Pneumococcal Polysaccharide Vaccine in Military Recruits

NCT02079701
View directory record Official record
Conditions
Pneumonia, Acute Respiratory Disease
Interventions
23-valent pneumococcal vaccine, Placebo
Biological
Lead sponsor
Naval Health Research Center
Federal
Eligibility
Not listed
Enrollment
152,723 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2007
U.S. locations
5
States / cities
San Diego, California • Great Lakes, Illinois • Fort Leonard Wood, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

NCT05412030
View directory record Official record
Conditions
Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions
AFX3772, Prevnar 13, Prevnar 20
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
42 Days to 90 Days
Enrollment
388 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
42
States / cities
Jonesboro, Arkansas • Los Angeles, California • Miami, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 17, 2026, 4:08 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine

NCT06337643
View directory record Official record
Conditions
Pneumococcal Vaccine
Interventions
MVX01, MVX01 Placebo
Biological
Lead sponsor
Matrivax Research and Development Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Savannah, Georgia • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Sep 17, 2026, 4:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Streptococcus Pneumonia: Effects of PCV13 on Pneumococcal Carriage

NCT01109108
View directory record Official record
Conditions
Nasopharyngeal Carriage of S. Pneumoniae
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
Not listed
Enrollment
9,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 17, 2026, 4:08 AM EDT
Completed No phase listed Observational

Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab

NCT03056924
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine
Biological
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2019 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

NCT05844423
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
42 Days to 89 Days
Enrollment
802 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
32
States / cities
Jonesboro, Arkansas • Madera, California • Tampa, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting No phase listed Observational

A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting

NCT05452941
View directory record Official record
Conditions
Pneumonia
Interventions
Diagnostic test on urine samples
Diagnostic Test
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
12,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
40
States / cities
El Centro, California • Fontana, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Results available

Pneumococcal Vaccines in Patients With Asthma

NCT03260790
View directory record Official record
Conditions
Asthma
Interventions
PCV13, PPSV23
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
19 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 17, 2026, 4:08 AM EDT
Completed No phase listed Observational

Epidemiologic Study Of The Distribution Of Vaccine-Type Streptococcus Pneumoniae Serotypes In Adults In The US With Community-Acquired Pneumonia

NCT01086397
View directory record Official record
Conditions
Pneumonia, Pneumococcal, Vaccines, Pneumococcal
Interventions
Urine sample collection
Procedure
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Mobile, Alabama • La Mesa, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 4 Interventional

Humoral Determinants of Immunity to Pneumococcal Infection

NCT00304382
View directory record Official record
Conditions
Pneumonia, Pneumococcal Infections, Infections, Streptococcus Pneumoniae
Interventions
Prevnar, Pneumovax
Biological
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Sep 17, 2026, 4:08 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

NCT07284654
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
31 valent pneumococcal conjugate vaccine, PCV20, PCV21
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4,049 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
30
States / cities
Birmingham, Alabama • Chinle, Arizona • Whiteriver, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of the Immune Response After Vaccination in Multiple Myeloma Patients

NCT02294487
View directory record Official record
Conditions
Multiple Myeloma, Myeloma, Multiple, Myeloma-Multiple
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Sep 17, 2026, 4:08 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

NCT07365826
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Fort Collins, Colorado • DeLand, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed No phase listed Observational

A Study To Examine Serologic Response In Hospitalized Patients Receiving Polyvalent Pneumococcal Vaccine

NCT00955851
View directory record Official record
Conditions
Pneumonia
Interventions
Pre and post vaccination titers
Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2010 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months

NCT01000311
View directory record Official record
Conditions
Meningococcal Disease
Interventions
MenACWY-CRM, DTaP-IPV/Hib, HBV, PCV, MMR
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
55 Days to 89 Days
Enrollment
529 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
42
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 17, 2026, 4:08 AM EDT
Completed No phase listed Observational

Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia

NCT05007860
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability.
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 17, 2026, 4:08 AM EDT
Active, not recruiting No phase listed Observational

A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia

NCT07251465
View directory record Official record
Conditions
Community-Acquired Pneumonia (CAP)
Interventions
Receipt of PCV20
Biological
Lead sponsor
Pfizer
Industry
Eligibility
19 Years and older
Enrollment
846,279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants

NCT06720038
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL dose of PCV20, 0.5 mL of the High-PFS dose VAX-31
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
42 Days to 89 Days
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
45
States / cities
Jonesboro, Arkansas • Gardena, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients

NCT00323557
View directory record Official record
Conditions
Leukemia
Interventions
Sargramostim (GM-CSF), Pneumococcal Vaccine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

NCT01924169
View directory record Official record
Conditions
Hematologic Disorder
Interventions
Lenalidomide, Influenza Vaccine, Pneumovax Vaccine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Sep 17, 2026, 4:08 AM EDT